 Peptide vaccines are broadly used as alternatives to traditional vaccines for cancer immunotherapy however the clinical translation of peptide vaccination is still limited by the low antitumor CD8

@highlight Co assembly of cationic epitope and CpG enables effective peptide vaccination.
@highlight Co assembled peptide CpG nanocomplex augments antitumor T cell responses.
@highlight Nanocomplex vaccination shows synergy with PD 1 blockade therapy.
@highlight Peptide CpG nanocomplex vaccine is promising for clinical translation.
